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KAJIAN IN- VITRO DAN PENDOKAN MOLEKUL TUJUH TUMBUHAN 
MYRTACEAE TERPILIH UNTUK AKTIVITI NEURAMINIDASE 
 
  
ABSTRAK 
 
Virus influenza A menyebabkan masalah kesihatan yang teruk kepada 
manusia dan beberapa spesies haiwan yang boleh membawa kepada morbiditi dan 
kematian dalam kalangan pesakit yang dijangkiti. Oseltamivir (Tamiflu) dan 
zanamavir (Relenza) adalah dua drug perencat NA terkini yang telah diluluskan oleh 
Pentadbiran Makanan dan Drug (FDA, USA). Walaubagaimana pun, oleh kerana 
kemunculan rintangan virus terhadap kedua-dua drug ini, terdapat keperluan 
mendesak untuk menemui suatu perencat neuraminidase alternatif. Kajian ini telah 
dijalankan untuk menyiasat aktiviti perencatan neuraminidase tujuh tumbuhan terpilih 
daripada keluarga Myrtaceae: P. guajava, S. cumini, S. grande, S. jambos, S. 
malaccense jambu bol, S. samaranges, dan S. malaccense jambu susu. Tumbuh-
tumbuhan telah diekstrak menggunakan metanol dan difraksi menggunakan n-
heksana, kloroform, etil asetat dan butanol. Minyak pati daripada daun tujuh terpilih 
ini telah diasingkan menggunakan hidropenyulingan  dan dianalisis dengan 
kromatografi-spektrometri jisim. Ekstrak mentah, fraksi, sebatian dan minyak pati 
telah diuji terhadap assai enzim neuraminidase Clostridium perfringens dan H1N1. 
Saringan maya menggunakan Autodock Vina terhadap tapak aktif protein 
neuraminidase H1N1 (kod PDB: 3TI6) telah digunakan untuk menyaring sebatian-
sebatian yang dikenal pasti daripada minyak pati, dan kemudian sebatian-sebatian 
yang dikenal pasti diubahsuai dengan menambahkan kumpulan fungsi yang ada pada 
oseltamivir iaitu drug piawai. Pemencilan  telah dilakukan dari fraksi etil asetat (daun 
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dan buah-buahan) daripada P. guajava untuk menghasilkan satu sebatian baru, 1,3-
benzotiazol-asid oksalik dan lima sebatian yang telah dikenali, asid kojik, asid galik, 
kuersetin, asid ursolik dan ursolik aldehid. Kebanyakan daripada ekstrak 
mempamerkan perencatan yang bagus, buah P. guajava 89% dan tujuh daun yang 
menpunyai kadar perencatan antara 70 hingga 89% bagi C. perfringens. Bagi fraksi 
yang lain, perencatan antara 12.2 hingga 97% terhadap NA daripada C. perfringens 
sementara  12.6 hingga 97.9%  terhadap NA daripada H1N1. Tiga pati minyak 
menunjukkan perencatan tinggi sehingga 57.8, 88.7 dan 91.2% dalam kalangan tujuh 
pati minyak. IC50 bagi dua sebatian terpencil, kuersetin adalah 229 µM, asid galik 
adalah 187 µM dan DANA 4.3 µM untuk NA bakteria, dan kuersetin 127 µM, asid 
galik 258 µM dan DANA 3.9 µM untuk NA virus H1N1. Pelbagai sebatian utama 
telah dikenalpasti daripada setiap varieti adalah 20.7% α-pinena daripada P. guajava, 
25.1% Z-β-osimena daripada S. cumini, 33.1% δ-terpinena daripada S. samarangense, 
(Z)-3-heksanol 23.5% daripada S. malaccense jambu susu dan 62.5%, 20.5% dan 
23.0% β-kariofilena masing-masing daripada S. grande, S.malaccense jambu bol dan 
S. Jambos. Pendokan molekul in silico sebatian terpencil daripada P. guajava dan 
sebatian yang dikenal pasti daripada minyak pati aktif telah dikaitkan dengan 
keputusan eksperimen. Semua sebatian mempamerkan interaksi dengan protein 
sasaran pada dua tapak mengikat berbeza, iaitu tapak aktif konservatif dan poket 
bersebelahan (kaviti 150). Hubungan antara in silico dan keputusan eksperimen 
menunjukkan bahawa aktiviti yang diperolehi bukan disebabkan oleh sebatian tunggal 
tetapi dari kesan sinergi, yang mana semua sebatian menyumbang untuk merencat 
neuraminidase. Kesimpulannya ekstrak mentah, fraksi, tiga daripada tujuh minyak 
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pati tumbuh-tumbuhan terpilih menunjukkan perencatan neuraminidase yang baik dan 
boleh menjadi sumber perencat neuraminidase. 
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IN-VITRO AND MOLECULAR DOCKING STUDIES OF SEVEN 
SELECTED MYRTACEAE PLANTS FOR NEURAMINIDASE ACTIVITY 
 
ABSTRACT 
Influenza A virus cause severe health problems to humans and several animal 
species which could result in morbidity and mortality in infected patients. Oseltamivir 
(Tamiflu) and zanamivir (Relenza) are two current drug used NA inhibitors that have 
been approved by the Food and Drug Administration (FAD, USA). However, due to 
the emergence of virus resistance to these drugs, there is an urgent need to discover 
an alternative neuraminidase inhibitors. The present study was undertaken to 
investigate the neuraminidase inhibition activity of seven selected plants that belong 
to the family of Myrtaceae; Psidium guajava, Syzygium cumini, Syzygium grande, 
Syzygium jambos, Syzygium malaccense cultivated jambu bol, Syzygium samaranges, 
and Syzygium malaccense cultivated jambu susu. The plants were extracted using 
methanol and fractionated using n-hexane, chloroform, ethyl acetate and butanol. 
Essential oils from leaves of seven selected plants were isolated by hydrodistillation 
and analyzed by head-space chromatography–mass spectrometry. The crude extract, 
fractions, compounds and essential oil were subjected to neuraminidase inhibition 
assay against Clostridium perfringens and H1N1 neuraminidase enzyme. Molecular 
docking using Autodocktools 4.2 were applied against the active site of neuraminidase 
H1N1 protein (PDB code: 3TI6) for the isolated and identified compounds from 
essential oil. The isolation was done from the ethyl acetate fraction of (leave and fruit) 
of P. guajava to yield one new compound 1,3-benzothiazole-oxalic acid and five 
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known compounds kojic acid, gallic acid, quercetin, ursolic acid and ursolic aldehyde. 
Good inhibition exhibited by most of the extracts, P. guajava fruit 89% and seven 
leaves ranging from 70 to 89% against C. perfringens. For the other fractions the 
inhibition ranged from 12.2 to 97% against NA from C. perfringens while 12.6-97.9% 
against NA from H1N1. Three essential oils showed high inhibition up to 57.8, 88.7 
and 91.2% among the seven oils. The IC50 of two isolated compounds quercetin was 
229 µM, gallic acid was 187 µM and DANA 4.3 µM for the bacterial NA, and 
quercetin was 127 µM, gallic acid was 258 µM and DANA 3.9 µM for the NA H1N1 
virus. Different major compounds identified in essential oil from each variety were 
20.7% α-pinene in P. guajava, 25.1% Z-β-ocimene in S. cumini, 33.1% δ-terpinene in 
S. samarangense, (Z)-3-hexanol (23.5%)  in S. malaccense cultivated jambu susu and 
62.5%, 20.5% and 23.0% β-caryophyllene in S. grande, S. malaccense cultivated 
jambu bol and S. Jambos, respectively. The in silico molecular docking of isolated 
compounds from P. guajava and identified compounds from active essential oil were 
correlated with the experimental results. All the compounds exhibited interactions 
with the target protein at two different binding sites, namely, conservative active site 
and adjacent pocket (150-cavity). The correlation between the in silico and 
experimental results revealed that the obtained activity was not due to a single 
compound but from a synergistic effect, where all the compounds contributed to 
inhibit neuraminidase. In conclusion crude extracts, fractions, three out of seven 
essential oils of selected plants showed good neuraminidase inhibition and could be 
source of neuraminidase inhibitors. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 The influenza A viruses 
 
 The human-human transmission rate of the influenza virus A (H1N1) virus 
and their effects on human health attracted global attention in 2009. Influenza A 
viruses are isolated from numerous host species, such as marine mammals, horses, 
pigs, domestic birds, humans, and dogs (Webster et al., 1992). Influenza A viruses 
belong to the Orthomyxoviridae family and cause infrequent epidemics that usually 
result in increased death rates compared with seasonal influenza epidemics. These 
viruses have an RNA genome consisting of eight gene segments (Knipe et al., 2007; 
Wright et al., 2007) with two neuraminidase (NA) and a hemagglutinin (HA) as 
surface glycoproteins in the envelope (Lamb et al., 2001; Wright et al., 2001). 
Influenza A viruses are sorted into antigenic HA and NA subtypes. A total of 16 
antigenic HA (H1–H16) and 9 NA (N1–N9) subtypes have been confirmed. H1N1, 
also called swine flu, consists of an H1 subtype HA and an N1 subtype NA (Schwahn 
et al., 2010). H3N2, H2N2, and H1N1 are considered the most important influenza A 
subtypes that infect humans during seasonal epidemics (Taubenberger et al., 2005). 
Influenza A viruses contain a genome consisting of eight segments involving a 
negative-sense, single-stranded RNA that encodes one or two proteins Figure 1.1. 
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Fig. 1.1 Schematic diagram of influenza A viruses (Horimoto and Kawaoka, 2005) 
 
1.2 Influenza pandemics  
Influenza viruses cause global pandemics as well as repeated epidemics. In the 
20th century, three major worldwide pandemics of influenza occurred at different 
interval in 1918, 1957, and 1968 (Taubenberger and Morens, 2006; Kilbourne, 2006). 
Spanish flu in 1918 was the most devastating pandemic that caused the death of 50 
million people (Johnson and Mueller, 2002). The subsequent epidemics in 1957 
occurred in Asia and Hong Kong flu pandemic of 1968; these two epidemics were 
milder, together caused a total of approximately two million deaths (Kilbourne, 2006). 
An important number of infected people would be detected resulting from the recently 
emerged H1N1 influenza virus and spread in many worldwide locations. In the 
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southwestern United States and Mexico 2009 new influenza A (H1N1) has been 
reported (Pan et al., 2010). During the epidemic 2009 H1N1 the new strain of swine 
flu (hosted by pigs) attracted the attentions of most of the organizations, because this 
epidemic gain the ability of transfer from human to human. 
1.3 Swine influenza virus (SIV) 
 
A global influenza preparedness has been developed by World Health 
Organization (WHO), this plan used to define the pandemic stages which can be used 
as national measures before and during the pandemic. Concerning the swine influenza 
(H1N1) pandemic, the WHO raised alert levels according to the different H1N1 
phases, namely phases 4, 5, and 6, on 27 April 2009, 29 April 2009, and 11 June 2009 
respectively, these grouped into six-phases, phase 1-3 correlate with preparedness 
these including the capacity development and the response planning activities, while 
or phases 4-6 gave clear signal the need for serious response and more mitigation 
efforts.. Afterward, the WHO declared a full-blown influenza pandemic. Laboratories 
showed genuine cases of H1N1 reported from more than 214 countries in June 2010, 
with the casualties reaching 18,156 (WHO, 2009). 
The pandemic H1N1 virus that spread in 2009 comprised various re-assorted 
viral genes from different sources. The virus was introduced to populations in 1998 
from the avian virus with a North American lineage; this H1N1 virus consisted of two 
polymerase genes, eight segmented genomic RNAs, PA, and PB2 (Krause µµ., 2010). 
Two different surface glycoproteins, NA and HA (Lamb and Krug, 2001; Wright and 
Webster, 2001), have important protective immunity within a host (Garten et al., 
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2009). This unique genetic combination may contribute to the improved fitness of the 
H1N1 in humans and its human-to-human transmissibility, No molecular functions 
have been shown before to confer the increased human-to-human transmissibility of 
the 2009 H1N1. 
1.4 Life cycle of influenza A virus  
The HA protein is critical for binding cellular receptors and fusing viral and 
endosomal membranes (Figure 1.2) (Das et al., 2010). The life cycle of the influenza 
A virus is divided into different stages: (1) viral entry to the host cell, (2) entry of viral 
ribonucleoprotein complex (vRNP) into the nucleus, (3) transcription and replication 
of the viral genome, (4) vRNP exportation from the nucleus (5) assembly, and then 
(6) budding at the plasma membrane of the host cell (Samji, 2009). 
 
Fig. 1.2 Schematic diagram of the influenza viral life cycle (Das et al., 2010). 
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Influenza is spread via tiny droplets expelled through coughing or sneezing, 
thus can be easily inhaled thereby transmitting the disease. Once the virus has entered 
the host within the respiratory tract, particularly in the nose, mouth and throat, it will 
fuse to the plasma membrane of permissive cells lining in the respiratory tract. The 
projecting spikes on the viral lipid membrane known as hemagglutinin (HA) bind to 
sialic acid (SA) of the host cell's membrane. Two major linkages between SA and the 
carbohydrates which are important for the HA specificity is the α (2, 3) and α (2, 6) 
found in different species (Samji, 2009). Humans influenza recognize α (2, 6) 
linkages, avian influenza; α (2, 3) linkages while swine influenza recognize both 
linkages (Skehel and Wiley, 2000). This explains the importance of swine being a 
good mixing vessel for avian and human influenza viruses, hence producing 
dangerous pathogenic viruses. 
After the attachment, receptor mediated endocytosis occurs and the virus is 
engulfed by the cell in an endosome at low pH of around 5 to 6. The acidic 
environment of the endosome induces conformational change in HA, bringing both 
the viral and endosomal membranes into contact with each other (Skehel and Wiley, 
2000; Huang et al., 2003)  and also opens up the  M2 ion channel that acts as a proton 
selective ion channel, thus acidifies the viral core (Pinto and Lamb, 2006; Holsinger 
et al., 1994). 
The viral constituents (vRNP) will then be released into the cytoplasm and 
migrate through the cytoplasm to the cell's nucleus. Viral transcription and replication 
occurs in the nucleus. The influenza viral genome is made up of negative sense strands 
of RNA and converted into a positive sense RNA for the genome to be transcribed. 
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The virus replicates its genome and forms new gene particles (Samji, 2009). New 
genes and proteins then migrate from the nucleus through the cytoplasm and to the 
cell membrane. The newly fanned viral begin to bud through the host cell's plasma 
membrane to form viral particles and eventually released into the extracellular 
environment to invade new cells (Scheiffele et al., 1999). The new viral particles are 
coated with sialic (neuraminic) acid (SA), the same substance that bound them to the 
exterior of the cell they had invaded   (Samji, 2009; Scheiffele et al., 1999). The 
nascent viruses would stick to the membrane of the cell in which they had been 
formed, thus, unable to separate and travel to other cells in the respiratory tract. 
The HA spike of one virus could stick to the SA coating of another, thereby 
causing viral aggregation and impeding the capability of the viruses to spread to, and 
invade, new cells. However, NA molecules, which are also part of the wrapping on 
the newly formed viral particles, cleave viral SA, thereby freeing the viruses from the 
host cell and from each other (Samji, 2009; Von Itzstein and Thomson, 2009). Drug 
that blocked the action of viral NA would thus prevent the escape of newly formed 
viruses from the host cells and thus preclude viral spread to other cells. This is the 
main reason as to why NA is taken as a drug target for developing agents in influenza 
virus drug discovery. 
1.5 Sialic acid  
Sialic acid (SA) is a common term for nine-carbon acidic amino sugars (5-
amino-3,5-dideoxy-D-glycero-D-galacto-nonulosonic acid). Two new compounds, 
namely, N-glycolylneuraminic acid and N-acetylneuraminic acid (Neu5Ac), are 
obtained by substituting the N-glycolyl group and N-acetyl with the amino group in 
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SA (Figure 1.3). The hydroxyl group can be substituted with phosphate, methyl, 
sulfate, or lactoyl residues (Suzuki et al., 2000). Human influenza viruses preferably 
bind to the sialic acid-α2,6-galactose SAα2,6Gal linkage, whereas equine and avian 
influenza viruses preferably bind to the (SAa2,3Gal) linkage (Connor et al., 1994). 
 
Fig. 1.3 Structure of (a) N-acetyl and (b) N-glycolylneuraminic acids. These SA differ 
at position 5 of the pyranose ring. N-Acetylneuraminic acid is the precursor of N-
glycolylneuraminic acid; enzymatic hydroxylation of the former results in the latter.  
 
1.6 Neuraminidase NA 
Influenza A viruses carry two surface glycoproteins, namely, HA and NA. 
Both proteins recognize the same host cell molecule, that is, SA and Neu5Ac, which 
are found as the terminal carbohydrate unit of the upper respiratory tract and lung-
associated glycoconjugates (Von Itzstein and Thomson, 2009). NA encodes six RNA 
segments and is known as the second major surface antigen of virions. NA acts as a 
pair of biological scissors clipping Neu5Ac residues, thus facilitating movement and 
viral release (Von Itzstein and Thomson, 2009). The NA morphology can be divided 
into three domains: the cytoplasmic domain of six amino acids, the N-terminal 
hydrophobic domain, and the actual stalk domain (Colman, 1994). The cytoplasmic 
domain contains six amino acids completely conserved in the NA of influenza A. This 
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condition is essential for NA inclusion into virions and for the assembly of the 
influenza A virus.  
Scientists have found nine different NAs (N9). However, only N1 and N2 are 
important in human infection, whereas the other NAs have only been found in seven 
animals. Neuraminidase is the major surface protein of the influenza virus that 
extracellularly acts by cleaving the terminal neuraminic acid from cellular receptors 
recognized by the HA. According to phylogenetic studies, the neuraminidase of the 
influenza virus is divided into two groups. Group one consist of N1, N4, N5, and N8, 
whereas the other group consist of N2, N3, N6, N7, and N9 (Gong et al., 2007).  
The neuraminidase plays an extremely important role in the pathogenesis of 
viral infection. That is, it facilitates the release of newly formed virions from the host 
cell surface to the neighbor cells that facilitated the spread of the virus. NA acts as a 
receptor-destroying enzyme in the influenza virus by removing the terminal SA of a 
viral receptor (De Clercq, 2006). 
 
1.7 Neuraminidase inhibitors (NAIs) 
 
Inhibitors block the active site of the neuraminidase and then prevent the 
release and spread of new virions. After infection, the patient should take an antiviral 
drug during the early stage if possible to achieve an effective treatment. Antiviral 
drugs are important role in the management of infection caused by the seasonal 
influenza virus. Adamantanes (M2 ion channel blockers) and NA inhibitors (NAIs) 
are two classes of antiviral drugs licensed to prevent and treat infections caused by 
the influenza A virus (Moscona, 2008). The first inhibitor analog of SA is 2,3-
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didehydro-2-deoxy-N-acetylneuraminic acid or Neu5Ac2en (DANA) Figure 1.4 
(Meindl et al., 1974).  
The only two drugs approved by the Food and Drug Administration, 
oseltamivir and zanamivir currently effective for the treatment of influenza infections, 
the seasonal influenza virus, and the pandemic H1N1 virus. Recently, peramivir has 
been developed as a new neuraminidase inhibitor administered intravenously (Babu 
et al., 2000) Figure 1.4. It is currently approved for emergency use in Japan and Korea. 
In other countries, this drug is still undergoing clinical trials. Peramivir is based on 
DANA, but it contains a cyclopentane ring and has the features of both oseltamivir 
and zanamivir Figure 1.4. Yamashita et al. (2010) found a new potent NA inhibitor, 
laninamivir considered as a second-generation acts as a long-acting NA inhibito. 
Administered as single inhaled dose, laninamivir is found to be effective against the 
wild-type strain of the influenza A and B viruses and the oseltamivir-resistant H274Y 
mutations of seasonal H1N1 viruses, namely, H5N1 and H1N1 (Sugaya and Ohashi, 
2010; Nguyen et al., 2010; Yamashita, 2010). 
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Fig. 1.4 Structures of (a) peramivir, (b) laninamivir, (c) oseltamivir, (d) zanamivir, (e) 
DANA. 
 
1.8 Neuraminidase Active Site 
The common feature among all influenza NAs is the active site Figure 1.5; 
with well formed large and rigid pockets form, can be considered as a common feature 
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among influenza NAs. SA and neuraminidase with conserved amino acids interact in 
a similar fashion with both substrate and inhibitor molecules (Xu et al., 2008; Kim et 
al., 1999). Therefore, antiviral drugs affecting the spread of viral replication have been 
developed.  
The presence of four hydrophobic residues and ten Arg, Asp, and Glu residues 
make the neuraminidase active site highly polar (Von Itzstein and Thomson, 2009; 
Zhang and Xu, 2006). The active site in NA is divided into five regions from S1 to 
S5. S1 includes Arg 118, Arg 292, and Arg 371, which all bind to the carboxylate of 
substrate. S2 consists of Glu 119 and Glu 227, which are acidic residues responsible 
for forming the negative-charge region of the active site (Zhang and Xu, 2006). The 
hydrophobic region present at S3 forms at the side chains of Ile 222 and Trp 178, 
which are adjacent to the polar region of the Arg 152 side chain, and interacts with 
water molecules (Zhang and Xu, 2006; Russell et al., 2006). S4 is primarily a 
hydrophobic region derived from the side chains of Ile 222, Ala 246, and Arg 224. S5 
has a mixed polarity and comprises of Ala 246 methyl and Glu 276 carboxylate that 
forms a hydrogen bond with the substrate hydroxyl group (Zhang and Xu, 2006).  
The joining pockets of eight highly conserved amino acid residues are linked 
together, thereby causing the NA active site of these amino acids to directly come into 
contact with Neu5Ac and its derivatives (Von Itzstein, 2007). The active site is 
divided into three major pockets according to the crystal structure. Pocket 1 is formed 
by Glu 276, Glu 277, and Asn 294, which interact with the glycerol moiety of SA 
(Zhang and Xu, 2006). Pocket 2 forms a hydrophobic pocket that is not utilized by 
sialic acid for binding (Kim et al., 1997) and comprises the Ala 246, Ile 222, and Arg 
224 side chains. Interactions with potential inhibitors are provided by these residues 
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because they are highly conserved. Pocket 3 is the largest pocket consisting of 
numerous amino acids, such as Glu 119, Asp 151, Arg 152, Trp 178, Ser 179, Th 222, 
and Glu 227, all of which interact with the N-acetyl and C-4 hydroxyl groups of sialic 
acid (Kim et al., 1997). 
 
Fig. 1.5 The neuraminidase active site, conserved NA residues (R118, D151, R152, 
R224, E227, E276, R292, and R371) (Yen et al., 2006) 
 
1.9 Natural products 
Natural products have many sources, such as microbes, plants, animals, or 
prebiotic origins (Vuorelaa et al., 2004). Many classes of compounds can be found in 
natural products. Natural products serve as natural sources of most drugs. Most of the 
useful therapeutic agents are derived from higher plants. In today’s clinical settings, 
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over 50% of all drugs are based on natural products and their analogs with 25% of 
such drugs containing higher plant-derived natural products (Balandrin et al., 1993).  
According to WHO, around 80% of people in developing countries depend on 
traditional medicine for their daily healthcare (WHO, 2009). Approximately 85% of 
these medicines are plant extracts; whereby, around 3.5 to 4 billion people worldwide 
rely on natural plants as drug sources (Farnsworth, 1988). Great efforts have been 
exerted to discover new antiviral drugs. Many reviews have published discoveries of 
new natural-based drugs for treating viral infections (Khan et al., 2005; Naithani et 
al., 2008). Different reviews have discussed the significant role of traditional 
medicine in the development and use of antiviral compounds. Traditional medicines 
such as Chakma medicines and Ayurvedic are interestingly good sources of potential 
antiviral drugs (Khan et al., 2005). Many active compounds from natural sources are 
used as therapeutics against different functionally diverse and genetic viruses; 
examples of these compounds include lignans, alkaloids, thiophenes, chlorophyllins, 
saponins, furyl compounds, limonoids, peptides, and proteins (Chattopadhyay and 
Bhattacharya, 2008; Naithani et al., 2008). The mechanism of anti-viral active 
compounds can be explained in terms of their scavenging capacities, DNA inhibition, 
antioxidant activities, RNA synthesis, and inhibition of viral reproduction 
(Chattopadhyay and Naik, 2007).  
According to several pharmacological and chemical studies, some bioactive 
compounds used to treat influenza are obtained from medicinal plants. Varieties of 
alkaloids, polyphenols, saponins, and flavonoids isolated from medicinal plants have 
been extensively tested for anti-influenza activity, which is reflected in the ability of 
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bioactive compounds to block adherence, duplication, penetration, and maturation 
during viral propagation (You et al., 2013). 
 Malaysia is home to over 15,000 species of flowering plants and more than 
1,100 species of fern allies and ferns, whereby most of the plants are known as 
endemic plants (Napis et al., 2001). A series of chemical structures can be observed 
in Malaysian flora, especially in secondary flora metabolites. Malaysian plants used 
as medicine by locals are well documented in books and papers on ethnobotany and 
ethnopharmacology, with about 1,300 plant species used for medicinal purposes 
(Napis et al., 2001). The traditional medicines available in the markets are mostly in 
crude form and are sold by traditional medical practitioners. Only 100 species from 
high-species density available have been systematically evaluated for medicinal 
properties (Napis et al., 2001). 
1.9.1 Family of Myrtaceae 
The Myrtaceae family known as a large family of more than 5,650 species is 
organized in 130 to 150 genera. This family is considered as the eighth largest 
flowering plant family. It has centers of diversity in the wet tropics, particularly South 
America, Australia, and tropical Asia with occurrences in Africa and Europe 
(Grattapaglia et al., 2010). 
The main genera are Eugenia, Syzygium, Psidium, Pimenta, Myrtus, 
Pseuocaryophyllus, Plinia, Leptospermum, Melaleuca, and Eucalyptus. Numerous 
members of this family are used in folk medicine for their antirheumatic, anti-
inflammatory, antidiarrheal, antioxidant, and antimicrobial properties (Govaerts et al., 
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2008). Syzygium gaertner is considered as the largest genus of the Myrtaceae family, 
with approximately 1,200 species distributed in subtropical and tropical regions 
(Biffin et al., 2010). Some promising fruits belonging to the Syzygium genus found in 
Malaysia are under-utilized but are recognized to be useful for medical and nutritional 
purposes. A number of species from the Syzygium genus have been cultivated for their 
edible, colorful flesh (Rabeta et al., 2013). 
1.9.1(a) Psidium guajava 
1.9.1(a)(i) General introduction  
P. guajava originated in Mexico (Rios et al., 1977) and extends throughout 
the South America, Europe, Africa, and Asia. Archaeological evidence shows that 
during pre-Columbian times, this plant was widely used and known in Peru. This plant 
can adapt to various climate conditions and is found in tropical and subtropical areas 
worldwide (Stone, 1970). P. guajava Linn. (Myrtaceae family) is commonly called 
guava, goyavier in French, goiabeiro in Portugal, banjiro in Japanese, and guaiaba in 
Brazil (Killion, 2000). P. guajava is known in Malaysian communities as jambu batu 
and is considered as an important food crop with medicinal use. P. guajava is a small, 
thin tree with a height of 10 m and a smooth peeling bark. It has a short petiolate 
leaves that are 5-15 cm long. Its flowers have whitish petals measuring up to 20 cm 
long as well as numerous stamens. The fruit is pear-shaped, small, 3-6 cm long and 
reddish-yellow when ripe (Stone, 1970). The P. guajava plants are shown in Figure 
1.6. 
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Fig. 1.6 Psidium guajava plants (a) flower, (b) fruit, (c) leaves and (d) tree (Finca 
Tropical 2011) 
 
 1.9.1(a)(ii) Traditional medicinal uses of Psidium guajava 
P. guajava was traditionally used as an anti-diarrheal agent and to treat 
dysentery. Its use as antioxidant, lipid lowering agent, and anti-bacterial agent and its 
hypoglycemic activities have also been reported (Rahmat et al., 2004). P. guajava is 
used in many parts of the world to treat different diseases and conditions, such as 
fever, pain, wounds, caries, inflammation, and diabetes, as reported in many ethno-
pharmacological studies (Table 1.1). 
a 
d c 
b 
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Table 1.1: Ethnomedical uses of Psidium guajava. 
Place, country Part(s) 
used 
Ethno medical uses Preparation(s) Reference 
Malaysia Leaves Vomiting, diarrhea and stomach ache Maceration  Alsarhan et al., 
2010 
 
Panama, Cuba, Costa Rica, 
M´exico,Nicaragua, Panam´a, 
Per´u, Venezuela, Mozambique, 
Guatemala, Argentina 
Leaves anti-inflammatory Externally applied hot 
on inflammations 
M´endez, 1990; 
Valdiz´an and 
Maldonado, 
1972 
Kinshasa, Congo 
  
Leaves, 
bark 
Diarrhoea, antiamoebic Infusion or decoction 
tisane 
Tona et al. 1999 
Latin America, 
Mozambique 
Leaves Diarrhoea, stomach ache Infusion or decoction Pontikis, 1996 
South Africa Leaves Diabetes mellitus, hypertension Infusion or decoction Oh et al., 2005; 
Ojewole, 2005 
China Leaves Diarrhoea, antiseptic, Diabetes mellitus Infusion or decoction Teixeira et al., 
2003 
Brazil Ripe 
fruit, 
flowers
, 
and 
leaves 
Anorexia, cholera, diarrhoea, digestive 
problems, dysentery, gastric insufficiency, 
inflamed mucous membranes, laryngitis, 
mouth 
(swelling), skin problems, sore throat, ulcers, 
vaginal discharge 
Mashed, Decoction Holetz et al., 
2002; Cybele et 
al., 1995 
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1.9.1(a)(iii) Chemical constituents of Psidium guajava 
P. guajava  contains many  phytochemicals including essential oils, 
polysaccharides, vitamins (Macleod and Troconis, 1975; Smith and Siwatibau, 1975), 
triterpenoid acid and  sesquiterpenoid alcohols (Begum et al., 2002; Wilson and Shaw, 
1978), saponins, flavonoids ,  steroids, tannins, glycosides, alkaloids,  (Geidam et al., 
2007; Narayana et al., 2001; Cho et al., 2003). P. guajava is very rich in vitamins and 
antioxidants and also has a high content of lycopene, lutein and zeaxanthine (Hobert 
and Tietze, 1998; Tee et al., 1997). The P. guajava fruit has high water content and 
low amounts of proteins, fats, and carbohydrates. This fruit also contains thiamine, 
iron, niacin, manganese, and vitamins A and C. Ascorbic acid is the major constituent 
of its skin (Gutierrez et al., 2008).  
Different compounds were isolated from fruits and leave of  P. guajava such 
as gallic acid  (1), protocatechuic acid (2), (Okuda et al., 1984) caffeic acid (Liang et 
al., 2005)  (3),  ferulic acid (Zhu et al., 1997) (4), chlorogenic acid (Liang et al., 2005) 
(5), ellagic acid (Misra and Seshadri, 1968) (6), quercetin (Liang et al., 2005) (7), 
leucocyanidin (Nadkarni and Nadkarni, 1999) (8), kaempferol (Liang et al., 2005)  
(9), quercetin 3-β-galactoside (Liang et al., 2005)  (10), kaempferol 3-β-glucoside 
(Liang et al., 2005)  (11), guaijaverin (Prabu et al., 2006)  (12), morin-3-O-α-L-
arabinopyranoside (Arima and Danno, 2002) (13), mecocyanin (Liang et al., 2005) 
(14), quercitrin (Liang et al., 2005) (15), zeatin riboside (Nagar and Rao, 1981) (16), 
oeanolic acid (Siddiqui et al., 2002) (17), ursolic acid (Begum et al., 2002) (18), β-
sitosterol (Begum et al., 2002) (19), uvaol (Begum et al., 2004) (20), goreishic acid I 
(Begum et al., 2002)  (21), 2-α-hydroxyursolic acid (Begum et al., 2002) (22), 
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guavanoic acid (Begum et al., 2004)  (23) , guavacoumaric acid (Begum et al., 2002) 
(24), guajavolide (Begum et al., 2004) (25), 2α-hydroxy-3β-P-E-coumaroyloxyurs-
12,18-dien-28-oic acid (Begum et al., 2002) (26), α-sitosterol-3-O-β-D-
glucopyranoside (Begum et al., 2002) (27).    
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1.9.1(a)(iv) Essential oil of Psidium guajava 
Analysis of essential oils from Psidium guajava (fruit and leaves) using GC 
and GC-MS enabled the identification different constituents varied from 
Monoterpenes and Sesquiterpenes. Essential oils are extracted from the fruit, leaves, 
and seeds of P. guajava. The yield and composition of the obtained oils vary from one 
part to another. Monoterpene hydrocarbon E-β-Ocimene, (Li et al., 1999) (28), Z-β- 
Ocimene (Li et al., 1999) (29),, Myrcene (Li et al., 1999) (30), p-cymene (Kenneth et 
al., 1970) (31),, α-pinene (Kenneth et al., 1970) (32), β-pinene (Jordan et al., 2003) 
(33), camphene (Jordan et al., 2003) (34), γ-terpinene (Jordan et al., 2003) (35) 
identified from leaves and fruits with different composition. Oxygenated 
monoterpenes identified from seed and leaves including 1,8-cineole (Kenneth et al., 
1970) (36), citronellol (Kenneth et al., 1970) (37) , linalool (Kenneth et al., 1970) 
(38), limonene (Kenneth et al., 1970) (39) . Sesquiterpenes hydrocarbon from bark, 
leaves and fruits include α-copaene (Oliver-Bever, 1986) (40), β-copaene (Adam et 
al., 2011) (41), 1-epi-cubenol (Ruther, 2000) (42), α-cubebene (Porat et al., 2001) 
(43), α-selinene (Ruther, 2000) (44), α-Humulene (Paniandy et al., 2000) (45) β-
caryophyllene (Adam et al., 2011) (46), γ-cadinene (Ruther, 2000) (47), germacrene 
D (Oliver-Bever, 1986) (48). Another important constituent oxygenated 
sesquiterpenes identified with GC-MS from leaves and fruits showed different 
composition include spathulenol (Porat et al., 2001) (59), ar-turmerone (Paniandy et 
al., 2000) (50), δ-cadinol (Ruther, 2000) (51), α-cadinol (Oliver-Bever, 1986) (52), 
caryophyllene oxide (Ruther, 2000) (53), humulene epoxide II (Paniandy et al., 2000) 
(54). 
